Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Catalyst Pharmaceuticals, Inc.'s quarterly P/E stands at 12.4x, down 8.1% year-over-year. EV/EBITDA has compressed 16.3% YoY to 7.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.68 | 12.38 | 14.59 | 11.73 | 13.23 | 13.47 | 11.86 | 14.20 | 11.73 | 20.97 | 13.56 | — | 10.18 |
| — | -8.1% | +23.0% | -17.4% | +12.8% | -35.8% | -12.5% | — | +15.3% | +31.6% | -35.9% | — | +16.2% | |
| P/S Ratio | 6.52 | 5.26 | 4.87 | 4.22 | 4.72 | 5.44 | 4.65 | 4.84 | 3.93 | 4.99 | 4.32 | 3.03 | 3.84 |
| — | -3.4% | +4.7% | -12.9% | +20.0% | +9.0% | +7.5% | +59.7% | +2.6% | -9.8% | -50.2% | -51.7% | +6.4% | |
| P/B Ratio | 4.18 | 3.10 | 3.11 | 2.72 | 3.23 | 3.88 | 3.62 | 3.77 | 3.17 | 3.50 | 4.93 | 3.57 | 4.07 |
| — | -20.0% | -14.1% | -27.9% | +1.9% | +10.6% | -26.5% | +5.5% | -22.1% | -38.1% | -29.9% | -32.8% | +28.1% | |
| P/FCF | 18.41 | 13.19 | 16.55 | 19.30 | 9.71 | 12.82 | 9.31 | 8.58 | 7.53 | 15.50 | 8.96 | 6.91 | 12.42 |
| — | +2.9% | +77.8% | +124.8% | +29.0% | -17.3% | +3.8% | +24.2% | -39.4% | — | -31.9% | -20.5% | +69.7% | |
| EV / EBITDA | 10.60 | 7.19 | 7.93 | 6.00 | 6.99 | 8.59 | 7.33 | 10.09 | 6.12 | 11.35 | 8.74 | — | 6.12 |
| — | -16.3% | +8.1% | -40.5% | +14.2% | -24.4% | -16.1% | — | +0.0% | +9.8% | -39.4% | — | +25.2% | |
| EV / EBIT | 12.16 | 8.16 | 9.15 | 6.39 | 7.64 | 9.87 | 8.44 | 10.09 | 7.18 | 15.30 | 10.66 | — | 7.24 |
| — | -17.4% | +8.4% | -36.6% | +6.4% | -35.5% | -20.9% | — | -0.8% | +24.9% | -22.5% | — | +48.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Catalyst Pharmaceuticals, Inc.'s operating margin was 49.0% in Q1 2026, up 8.5 pp QoQ and up 4.2 pp YoY. The trailing four-quarter average of 44.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 4.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.2% | 83.8% | 82.9% | 82.9% | 79.6% | 87.3% | 84.7% | 85.0% | 87.4% | 87.3% | 85.7% | 86.2% | 87.9% |
| — | -4.0% | -2.2% | -2.4% | -9.0% | +0.1% | -1.1% | -1.4% | -0.5% | -1.2% | +5.1% | +3.7% | +2.7% | |
| Operating Margin | 43.8% | 49.0% | 40.5% | 44.7% | 45.2% | 44.8% | 44.3% | 39.6% | 44.2% | 27.5% | 37.7% | -36.2% | 46.9% |
| — | +9.4% | -8.5% | +12.9% | +2.3% | +62.7% | +17.5% | +209.2% | -5.7% | -34.0% | -25.6% | -182.6% | -12.8% | |
| Net Margin | 36.4% | 42.7% | 34.5% | 35.6% | 35.6% | 40.1% | 39.4% | 34.1% | 33.2% | 23.6% | 31.5% | -30.0% | 37.9% |
| — | +6.3% | -12.5% | +4.3% | +6.9% | +69.8% | +25.2% | +213.8% | -12.3% | -31.8% | -24.8% | -175.4% | -6.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.5% | 6.5% | 5.6% | 5.9% | 6.3% | 7.5% | 8.1% | 6.9% | 7.0% | 4.9% | 9.5% | -8.5% | 10.7% |
| — | -13.1% | -30.2% | -14.0% | -9.4% | +52.1% | -14.9% | +181.3% | -34.5% | -47.4% | +6.0% | -195.5% | +13.7% | |
| ROA | 21.9% | 5.7% | 4.9% | 5.2% | 5.5% | 6.4% | 6.9% | 5.9% | 6.0% | 4.2% | 7.9% | -7.2% | 8.9% |
| — | -12.3% | -29.1% | -12.1% | -8.1% | +54.7% | -12.7% | +182.7% | -32.0% | -44.8% | +9.8% | -194.7% | +5.5% | |
| ROIC | 83.8% | 21.6% | 19.3% | 22.6% | 23.5% | 22.1% | 21.7% | 16.7% | 16.6% | 8.0% | 12.9% | -12.9% | 18.0% |
| — | -2.1% | -11.0% | +35.7% | +41.8% | +176.1% | +68.0% | +228.9% | -7.8% | -70.8% | -93.3% | -117.9% | -66.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Catalyst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, down from 0.0x last quarter — comfortably within a safe range. The current ratio has improved 15.6% YoY to 7.10x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -32.0% | -33.3% | -36.8% | -37.0% | -37.0% | -52.2% | -52.5% | -44.2% | -45.9% | -29.3% | -29.0% | -40.9% | |
| Debt / EBITDA | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.09 | 0.07 | — | 0.07 |
| — | -24.0% | -11.5% | -40.8% | -25.5% | -55.3% | -37.0% | — | -21.4% | +5.0% | -43.4% | — | -52.4% | |
| Current Ratio | 6.08 | 7.10 | 6.08 | 6.62 | 6.71 | 6.14 | 5.17 | 5.11 | 5.14 | 5.09 | 2.88 | 3.32 | 4.59 |
| — | +15.6% | +17.6% | +29.5% | +30.6% | +20.8% | +79.2% | +54.0% | +12.0% | +45.0% | -48.2% | -46.3% | -57.4% | |
| Quick Ratio | 5.82 | 6.84 | 5.82 | 6.40 | 6.55 | 5.96 | 5.01 | 4.92 | 4.94 | 4.83 | 2.68 | 3.17 | 4.38 |
| — | +14.7% | +16.3% | +30.1% | +32.5% | +23.4% | +86.9% | +55.6% | +12.8% | +45.4% | -50.9% | -47.5% | -58.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -140.33 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CPRX stock.
Catalyst Pharmaceuticals, Inc.'s current P/E is 18.7x. The average P/E over the last 4 quarters is 13.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Catalyst Pharmaceuticals, Inc.'s current operating margin is 43.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Catalyst Pharmaceuticals, Inc.'s business trajectory between earnings reports.